Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease.

Dransfield MT, Harnden S, Burton RL, Albert RK, Bailey WC, Casaburi R, Connett J, Cooper JA, Criner GJ, Curtis JL, Han MK, Make B, Marchetti N, Martinez FJ, McEvoy C, Nahm MH, Niewoehner DE, Porszasz J, Reilly J, Scanlon PD, Scharf SM, Sciurba FC, Washko GR, Woodruff PG, Lazarus SC; NIH COPD Clinical Research Network.

Clin Infect Dis. 2012 Sep;55(5):e35-44. Epub 2012 May 31.

2.

Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease.

Dransfield MT, Nahm MH, Han MK, Harnden S, Criner GJ, Martinez FJ, Scanlon PD, Woodruff PG, Washko GR, Connett JE, Anthonisen NR, Bailey WC; COPD Clinical Research Network.

Am J Respir Crit Care Med. 2009 Sep 15;180(6):499-505. doi: 10.1164/rccm.200903-0488OC. Epub 2009 Jun 25.

3.

13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.

De Montalembert M, Abboud MR, Fiquet A, Inati A, Lebensburger JD, Kaddah N, Mokhtar G, Piga A, Halasa N, Inusa B, Rees DC, Heath PT, Telfer P, Driscoll C, Al Hajjar S, Tozzi A, Jiang Q, Emini EA, Gruber WC, Gurtman A, Scott DA.

Pediatr Blood Cancer. 2015 Aug;62(8):1427-36. doi: 10.1002/pbc.25502. Epub 2015 Mar 23.

PMID:
25810327
4.

Comparison of the immunogenicity and safety of polysaccharide and protein-conjugated pneumococcal vaccines among the elderly aged 80 years or older in Japan: an open-labeled randomized study.

Namkoong H, Funatsu Y, Oishi K, Akeda Y, Hiraoka R, Takeshita K, Asami T, Yagi K, Kimizuka Y, Ishii M, Tasaka S, Suzuki Y, Iwata S, Betsuyaku T, Hasegawa N.

Vaccine. 2015 Jan 3;33(2):327-32. doi: 10.1016/j.vaccine.2014.11.023. Epub 2014 Nov 22.

5.

Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine.

Thisyakorn U, Chokephaibulkit K, Kosalaraksa P, Benjaponpitak S, Pancharoen C, Chuenkitmongkol S.

Hum Vaccin Immunother. 2014;10(7):1859-65. doi: 10.4161/hv.28642.

6.

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.

Esposito S, Tansey S, Thompson A, Razmpour A, Liang J, Jones TR, Ferrera G, Maida A, Bona G, Sabatini C, Pugni L, Emini EA, Gruber WC, Scott DA, Principi N.

Clin Vaccine Immunol. 2010 Jun;17(6):1017-26. doi: 10.1128/CVI.00062-10. Epub 2010 Apr 28.

7.
9.

Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial.

Juergens C, de Villiers PJ, Moodley K, Jayawardene D, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

Hum Vaccin Immunother. 2014;10(5):1343-53. doi: 10.4161/hv.27998. Epub 2014 Feb 27.

10.

Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.

Glesby MJ, Watson W, Brinson C, Greenberg RN, Lalezari JP, Skiest D, Sundaraiyer V, Natuk R, Gurtman A, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

J Infect Dis. 2015 Jul 1;212(1):18-27. doi: 10.1093/infdis/jiu631. Epub 2014 Nov 13.

PMID:
25395187
11.

Immune response to pneumococcal conjugate vaccination in asplenic individuals.

Stanford E, Print F, Falconer M, Lamden K, Ghebrehewet S, Phin N, Baxter D, Helbert M, McCann R, Andrews N, Balmer P, Borrow R, Kaczmarski E.

Hum Vaccin. 2009 Feb;5(2):85-91. Epub 2009 Feb 7.

PMID:
18758242
12.

Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients.

Migita K, Akeda Y, Akazawa M, Tohma S, Hirano F, Ideguchi H, Kozuru H, Jiuchi Y, Matsumura R, Suematsu E, Miyamura T, Mori S, Fukui T, Izumi Y, Iwanaga N, Tsutani H, Saisyo K, Yamanaka T, Ohshima S, Mori N, Matsumori A, Takahi K, Yoshizawa S, Kawabe Y, Suenaga Y, Ozawa T, Hamada N, Komiya Y, Matsui T, Furukawa H, Oishi K.

Arthritis Res Ther. 2015 Dec 10;17:357. doi: 10.1186/s13075-015-0863-3.

13.

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccines.

Kim DS, Shin SH, Lee HJ, Hong YJ, Lee SY, Choi KM, Oh CE, Kim KH, Juergens C, Patterson S, Giardina PC, Gruber WC, Emini EA, Scott DA.

Pediatr Infect Dis J. 2013 Mar;32(3):266-73. doi: 10.1097/INF.0b013e3182748bb6.

PMID:
23011012
14.

Post hoc analysis of a randomized double-blind trial of the correlation of functional and binding antibody responses elicited by 13-valent and 7-valent pneumococcal conjugate vaccines and association with nasopharyngeal colonization.

Juergens C, Patterson S, Trammel J, Greenberg D, Givon-Lavi N, Cooper D, Gurtman A, Gruber WC, Scott DA, Dagan R.

Clin Vaccine Immunol. 2014 Sep;21(9):1277-81. doi: 10.1128/CVI.00172-14. Epub 2014 Jul 2.

15.

Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.

Cho BH, Stoecker C, Link-Gelles R, Moore MR.

Vaccine. 2013 Dec 5;31(50):6011-21. doi: 10.1016/j.vaccine.2013.10.024. Epub 2013 Oct 19.

PMID:
24148572
16.

A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil.

Weckx LY, Thompson A, Berezin EN, de Faria SM, da Cunha CA, Pride M, Patterson S, Gruber WC, Emini EA, Scott DA; 012 Study Group.

Vaccine. 2012 Dec 14;30(52):7566-72. doi: 10.1016/j.vaccine.2012.10.040. Epub 2012 Oct 22.

PMID:
23099331
17.

13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial.

Silfverdal SA, Flodmark CE, Rombo L, Tansey SP, Sidhu M, Trammel J, Emini EA, Gruber WC, Scott DA, Gurtman A; 3012 study group.

Vaccine. 2013 Feb 18;31(9):1284-92. doi: 10.1016/j.vaccine.2012.12.066. Epub 2013 Jan 7.

PMID:
23306363
18.

Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label study.

Cordonnier C, Ljungman P, Juergens C, Maertens J, Selleslag D, Sundaraiyer V, Giardina PC, Clarke K, Gruber WC, Scott DA, Schmoele-Thoma B; 3003 Study Group.

Clin Infect Dis. 2015 Aug 1;61(3):313-23. doi: 10.1093/cid/civ287. Epub 2015 Apr 13.

19.

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine.

Bryant KA, Frenck R, Gurtman A, Rubino J, Treanor J, Thompson A, Jones TR, Sundaraiyer V, Baxter LM, Gruber WC, Emini EA, Scott DA, Schmoele-Thoma B.

Vaccine. 2015 Oct 26;33(43):5854-60. doi: 10.1016/j.vaccine.2015.08.080. Epub 2015 Sep 9.

PMID:
26362099
20.

Host-pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease.

Bogaert D, van der Valk P, Ramdin R, Sluijter M, Monninkhof E, Hendrix R, de Groot R, Hermans PW.

Infect Immun. 2004 Feb;72(2):818-23.

Supplemental Content

Support Center